Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Aging Cell
Autors principals: Arriola Apelo, Sebastian I., Neuman, Joshua C., Baar, Emma L., Syed, Faizan A., Cummings, Nicole E., Brar, Harpreet K., Pumper, Cassidy P., Kimple, Michelle E., Lamming, Dudley W.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4717280/
https://ncbi.nlm.nih.gov/pubmed/26463117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acel.12405
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars